These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11506095)

  • 21. Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers.
    Zuurman L; Passier PC; de Kam ML; Kleijn HJ; Cohen AF; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1689-96. PubMed ID: 19939872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new era for sedation in ICU patients.
    Wunsch H; Kress JP
    JAMA; 2009 Feb; 301(5):542-4. PubMed ID: 19188333
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacoeconomic modeling of lorazepam, midazolam, and propofol for continuous sedation in critically ill patients.
    MacLaren R; Sullivan PW
    Pharmacotherapy; 2005 Oct; 25(10):1319-28. PubMed ID: 16185175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam.
    Lau CE; Wang Y; Ma F
    Eur J Pharmacol; 1998 Apr; 346(2-3):131-44. PubMed ID: 9652352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.
    Aoyama T; Hirata K; Yamamoto Y; Yokota H; Hayashi H; Aoyama Y; Matsumoto Y
    J Clin Pharm Ther; 2016 Aug; 41(4):392-8. PubMed ID: 27178380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting.
    Zomorodi K; Donner A; Somma J; Barr J; Sladen R; Ramsay J; Geller E; Shafer SL
    Anesthesiology; 1998 Dec; 89(6):1418-29. PubMed ID: 9856717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit.
    Barr J; Donner A
    Crit Care Clin; 1995 Oct; 11(4):827-47. PubMed ID: 8535981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing dexmedetomidine with midazolam for sedation of patients in the ICU.
    DePriest J; Gonzalez L
    JAMA; 2009 Jun; 301(23):2439; author reply 2441-2. PubMed ID: 19531777
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparing dexmedetomidine with midazolam for sedation of patients in the ICU.
    Rady MY; Patel BM; Larson JS
    JAMA; 2009 Jun; 301(23):2439-40; author reply 2441-2. PubMed ID: 19531776
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.
    Fiset P; Lemmens HL; Egan TD; Shafer SL; Stanski DR
    Clin Pharmacol Ther; 1995 Nov; 58(5):567-82. PubMed ID: 7586951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients.
    Ethuin F; Boudaoud S; Leblanc I; Troje C; Marie O; Levron JC; Le Moing JP; Assoune P; Eurin B; Jacob L
    Intensive Care Med; 2003 Nov; 29(11):1916-20. PubMed ID: 12923616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptation of non-linear mixed amount with zero amount response surface model for analysis of concentration-dependent synergism and safety with midazolam, alfentanil, and propofol sedation.
    Liou JY; Ting CK; Teng WN; Mandell MS; Tsou MY
    Br J Anaesth; 2018 Jun; 120(6):1209-1218. PubMed ID: 29793588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing dexmedetomidine with midazolam for sedation of patients in the ICU.
    Gupta A; Lee D; Su M
    JAMA; 2009 Jun; 301(23):2440-1; author reply 2441-2. PubMed ID: 19531778
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparing dexmedetomidine with midazolam for sedation of patients in the ICU.
    Paciullo C
    JAMA; 2009 Jun; 301(23):2440; author reply 2441-2. PubMed ID: 19531779
    [No Abstract]   [Full Text] [Related]  

  • 35. Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
    Sackey PV; Martling CR; Carlswärd C; Sundin O; Radell PJ
    Crit Care Med; 2008 Mar; 36(3):801-6. PubMed ID: 18431266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoeconomics of sedation in the ICU.
    Dasta JF; Kane-Gill S
    Crit Care Clin; 2009 Jul; 25(3):571-83, ix. PubMed ID: 19576531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia.
    Bastiaans DE; Swart EL; van Akkeren JP; Derijks LJ
    Int J Clin Pharm; 2013 Apr; 35(2):210-6. PubMed ID: 23192725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complications of Sedation in Critical Illness: An Update.
    Foster J
    Crit Care Nurs Clin North Am; 2016 Jun; 28(2):227-39. PubMed ID: 27215360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.
    Boulieu R; Lehmann B; Salord F; Fisher C; Morlet D
    Eur J Drug Metab Pharmacokinet; 1998; 23(2):255-8. PubMed ID: 9725490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altering intensive care sedation paradigms to improve patient outcomes.
    Riker RR; Fraser GL
    Crit Care Clin; 2009 Jul; 25(3):527-38, viii-ix. PubMed ID: 19576528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.